STOCK TITAN

Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Aptorum Group (NASDAQ: APM) has announced the granting of its first patent for SACT-1, a repurposed drug aimed at treating various cancers, including neuroblastoma. This patent, numbered 11,166,962 B2, provides intellectual property protection for the drug's composition and its method of use in conjunction with other treatments. The company also revealed plans to pursue further patent protection and initiate Phase Ib/2a clinical trials for SACT-1 pending IND clearance. This milestone is crucial for protecting their investment and advancing their oncology pipeline.

Positive
  • Patent granted for SACT-1, enhancing IP protection.
  • Potential to treat neuroblastoma and other cancers.
  • Plans for Phase Ib/2a clinical trials indicate ongoing development.
Negative
  • None.

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- Regulatory News:

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office has granted the first patent regarding Aptorum’s SACT-1 repurposed drug for the treatment of various cancers including but not limited to neuroblastoma (US Patent 11,166,962 B2).

The SACT-1 invention provides a composition and method for treating or preventing the growth of cancerous tumors and/ or delaying the onset of cancer from tumor-initiating cells. The composition is administered alone or in combination with one or more chemotherapeutic agents, biological agents, and/or anticancer agents by various routes of administration and dosage forms.

Mr Darren Lui, President and Executive Director of Aptorum Group says, “In addition to our previous announcement of the completion of our Phase 1 clinical trial of SACT-1 on January 10, 2022, we are pleased to have received the granted patent from the USPTO on our drug candidate. As IP protection is critically important for protecting our investment in developing repurposed drugs, the granted patent will further support our ongoing development effort of SACT-1 as a potentially effective treatment of neuroblastoma and other cancer types. We will be actively seeking further IP protection on our SACT-1 repurposed drug via patent applications in major jurisdictions and the embarking of the exciting Phase Ib/2a clinical trials for SACT-1, subject to IND clearance in 2022.”

About SACT-1

SACT-1 is an orally administered repurposed small molecule drug to target neuroblastoma. SACT-1’s mechanism has been investigated in our preclinical studies to enhance tumor cell death and suppress MYCN expression (a common clinical diagnosis in high-risk or relapsed neuroblastoma patients where an amplification of MYCN is usually observed). SACT-1 is designed to be used especially in combination with standard-of-care chemotherapy.

About Aptorum Group Limited

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development of a novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore’s Agency for Science, Technology and Research.

For more information about Aptorum Group, please visit www.aptorumgroup.com.

Disclaimer and Forward-Looking Statements

This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the US Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future, as well as the prospectus that received the French Autorité des Marchés Financiers visa n°20-352 on 16 July 2020. As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein.

Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

This announcement is not a prospectus within the meaning of the Regulation (EU) n°2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n°2019/980 of 14 March 2019 and n°2019/979 of 14 March 2019.

This press release is provided “as is” without any representation or warranty of any kind.

Aptorum Group Limited

Investor Relations Department

investor.relations@aptorumgroup.com

+44 20 80929299

Redchip – Financial Communications United States

Investor relations

Dave Gentry

dave@redchip.com

+1 407 491 4498

Actifin – Financial Communications Europe

Investor relations

Ghislaine Gasparetto

ggasparetto@actifin.fr

+33 1 56 88 11 22

Source: Aptorum Group Limited

FAQ

What is the significance of Aptorum Group's new patent for SACT-1?

The new patent protects the composition and method of use for SACT-1, a repurposed drug for treating various cancers, crucial for securing investment and future development.

When did Aptorum Group complete the Phase 1 clinical trial for SACT-1?

Aptorum Group completed the Phase 1 clinical trial for SACT-1 on January 10, 2022.

What are Aptorum Group's plans for SACT-1 following the patent grant?

Aptorum Group plans to seek further patent protections and initiate Phase Ib/2a clinical trials for SACT-1, subject to IND clearance in 2022.

What types of cancer does SACT-1 aim to treat?

SACT-1 primarily targets neuroblastoma, but it is also aimed at treating various other cancers.

What role does intellectual property play in Aptorum Group's strategy?

Intellectual property protection is crucial for Aptorum Group as it safeguards investments in the development of repurposed drugs like SACT-1.

Aptorum Group Limited

NASDAQ:APM

APM Rankings

APM Latest News

APM Stock Data

7.82M
2.94M
24.6%
2.06%
0.05%
Biotechnology
Healthcare
Link
United States of America
London